vivoPharma opens US preclinical facility

By Gareth Macdonald

- Last updated on GMT

Related tags North america

Australian preclinical services firm vivoPharma has opened a new vivarium and laboratory facility in the US as part of an effort to expand its global reach.

The contract research organisation (CRO) said it plans to use the new preclinical services unit in Hershey, Pennsylvania as a “sounding board for building new business engagements and maintaining strong relationships with existing clients in the US.”

The US opening comes just a few weeks​ after vivoPharm partnered with Michigan-based contract services firm MPI Research in a deal designed to further the development of effective oncology models for preclinical research.

At the time company VP of global development Fernando Felquer told “This partnership will bring in revenue which in effect opens up the US market for us​,” adding that an “alliance with a large American CRO will help to put us on the map​.”

US preclinical market

vivoPharma is one of a number of non-US preclinical research organisations to have expanded in North America over the last 12 months citing the market's revenue potential as a major motivation.

Last August​, for example, UK-based firm Cyprotex bought US counterpart Apredica, highlighting the firm's position in the US ADME toxicity testing services market as the major attraction and predicting sales growth as a result.

This forecast was confirmed last month​ when Cyprotex revealed that the performance of its US operation was the key to the 43 per cent increase in revenue it achieved in the second quarter.

Also, in June​ this year French preclinical CRO CITox launched CIToxLAB, a new organisation formed following its acquisition of Canadian preclinical CRO Lab Research in April​.

Speaking ahead ​of the launch CITox executive chairman Jean-Francois Le Bigot told that a key driver for the acquisition had been LAB’s facility in Laval, Canada from where his firm “can serve the entire North American market​.”

And, more recently​ another UK-based preclinical CRO and discovery services provider, Selcia, opened a new facility in Massachuesetts. Again the firm said that growth of its US business was the main reason for the expansion.

Related news

Show more

Related products

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

How Sponsors Reduce Chaos in Decentralized Trials

How Sponsors Reduce Chaos in Decentralized Trials

Content provided by Florence Healthcare | 08-Mar-2023 | Insight Guide

89% of research sponsors currently use and expect to continue the use of decentralized technologies and methods, according to our state of the industry...

Related suppliers

Follow us


View more